Table 1.
Characteristic | Buprenorphine Implant Group n=114 |
Placebo Implant Group n=54 |
Sublingual Buprenorphine n=119 |
---|---|---|---|
Age, mean (SD), y | 36.4 (11.0) | 35.2 (10.3) | 35.3 (10.9) |
Male, No. (%) | 72 (63.2) | 31 (57.4) | 72 (60.5) |
Race, N (%) | |||
White | 95 (83.3) | 45 (83.3) | 97 (81.5) |
Black | 14 (12.3) | 7 (13.0) | 16 (13.4) |
Other | 5 (4.4) | 2 (3.8) | 6 (5.0) |
Hispanic Ethnicity, N(%) | 24 (21.1) | 11 (20.4) | 17 (14.3) |
Primary opioid of abuse, N (%) | |||
Heroin | 76 (66.7) | 28 (51.9) | 75 (63.0) |
Prescription pain med. | 38 (33.3) | 26 (48.1) | 43 (36.1) |
Other | 0 | 0 | 1 (0.8) |
Diagnosis of opioid dependence for > 5 years, N (%) | 29 (25.4) | 12 (22.2) | 37 (31.1) |
Previous treatment for opioid Dependence, N (%) | 63 (55.3) | 31 (57.4) | 68 (57.1) |